- Emyria (EMD) pens a master services agreement (MSA) with US-based preclinical contract research organisation, Calvert Labs
- Calvert will design and deliver a range of preclinical and optimisation studies targeting TGA and FDA registration of EMD’s synthetic cannabinoid platform
- The first study is expected to begin in October and will assist Emyria in finalising dose formation ahead of starting clinical trials
- Shares were trading up 1.28 per cent at 19.8 cents 3:55 pm AEST
Drug developer Emyria (EMD) has signed a master services agreement (MSA) with US-based preclinical contract research organisation, Calvert Labs.
The deal will see Calvert Labs design and deliver a range of preclinical studies targeting registration of EMD’s novel synthetic cannabinoid (CBD) platform with the Therapeutic Goods Administration (TGA) and US Food and Drug Administration (FDA).
Accordingly, Calvert will focus on generating preliminary toxicology and pharmacokinetics data to enable human clinical trials of the product, with complementary bioanalyses to be conducted by Altascience Company in Quebec.
Emyria’s managing director Michael Winlo said EMD was delighted to partner with Calvert Labs.
“This preclinical work will help strengthen Emyria’s intellectual property relating to our synthetic cannabinoid platform,” he said.
“Importantly, this work will help guide the novel formulation, delivery and dosing strategies of our platform as we prepare our drug-one development programs for pivotal clinical trials.”
The first study is expected to commence in October and will assist Emyria in finalising dose formation ahead of pivotal trials.
Shares were trading up 1.28 per cent at 19.8 cents 3:55 pm AEST.